ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CM529D1

Its studies are led by Keymed Biosciences.

Furthest: phase 2, since Oct 16, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keymed Biosciences11 open or runningphase 2since Oct 16, 2026Oct 16, 2026Dec 31, 2029phase 2 · NCT07893171

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 16, 2026First study: phase 2 study in Advanced Solid TumorsFirst studyNCT07893171 · 128 planned · China

Ahead

  1. Dec 31, 2029Primary completion: phase 2 study in Advanced Solid TumorsNCT07893171

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07893171Advanced Solid Tumors · China2Not yet recruitingDec 31, 2029128

How it is read

Names in the registry

  • “CM529D1”, 3 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.